Implementation of a new analyzer in CELA

27/03/25

From March 31, 2025, the Central Donor Laboratory of Belgian Red Cross-Flanders (CELA) will operate the Roche® cobas pure device for performing diagnostic tests on blood donors on EDTA plasma. 

We are taking out the Abbott® Architect device on which CELA has been determining CMV IgM and IgG and aHBs for many years.

Some tests previously outsourced will be performed in-house. These tests are: Total protein , HTLV-I/II screening, Trypanosoma cruzi screening.

This will make the blood establishment's blood product release services more efficient.